U.S. Lawmakers to Review Unredacted Jeffrey Epstein DOJ Files Starting Monday 
Japan Economy Poised for Q4 2025 Growth as Investment and Consumption Hold Firm 
South Africa Eyes ECB Repo Lines as Inflation Eases and Rate Cuts Loom 
Newly Released DOJ Epstein Files Expose High-Profile Connections Across Politics and Business 
Federal Judge Blocks Trump Administration Move to End TPS for Haitian Immigrants 
Gold and Silver Prices Rebound After Volatile Week Triggered by Fed Nomination 
China Extends Gold Buying Streak as Reserves Surge Despite Volatile Prices 
Gold Prices Slide Below $5,000 as Strong Dollar and Central Bank Outlook Weigh on Metals 
Supreme Court Signals Skepticism Toward Hawaii Handgun Carry Law 
U.S. Condemns South Africa’s Expulsion of Israeli Diplomat Amid Rising Diplomatic Tensions 
CK Hutchison Unit Launches Arbitration Against Panama Over Port Concessions Ruling 
Trump Lifts 25% Tariff on Indian Goods in Strategic U.S.–India Trade and Energy Deal 
Jerome Powell Attends Supreme Court Hearing on Trump Effort to Fire Fed Governor, Calling It Historic 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
Minnesota Judge Rejects Bid to Halt Trump Immigration Enforcement in Minneapolis 
Federal Judge Signals Possible Dismissal of xAI Lawsuit Against OpenAI 
Citigroup Faces Lawsuit Over Alleged Sexual Harassment by Top Wealth Executive 
Johnson & Johnson disclosed that it spent $800 million in settling "substantially all" of the roughly 9,000 cases by men who claimed having developed excessive breast tissue in using the company's antipsychotic drug Risperdal.
The company said it reached the agreement with lawyers handling the cases, including a lawsuit in Philadelphia by Maryland resident Nicholas Murray, who was awarded an $8 billion in punitive damage by a jury award in 2019. A judge has since reduced the award to $6.8 million.
The lawsuits, filed in Pennsylvania, California, and Missouri, generally accused J&J of failing to warn of the risk called gynecomastia associated with Risperdal, which they claimed were marketed for off-label, unapproved uses with children.
The company denied the allegations.
In 1993, the US Food and Drug Administration approved Risperdal for treating schizophrenia and bipolar mania in adults. It was only in 2006 that it was approved for treating irritability associated with autism in children.
The company separately agreed in 2013 to pay $2.2 billion to settle US criminal and civil probes into its marketing of Risperdal and two other drugs.
In May, the US Supreme Court rejected J&J's bid to overturn a $70 million jury verdict against it for its failure to warn about risks associated with using Risperdal.
